{"id":"trifluridine-and-tipiracil-hydrochloride","safety":{"commonSideEffects":[{"effect":"Fatigue","drugRate":"38.8%","placeboRate":"","totalAtRisk":529,"totalAffected":205,"trialsReporting":8},{"effect":"Nausea","drugRate":"35.0%","placeboRate":"","totalAtRisk":529,"totalAffected":185,"trialsReporting":8},{"effect":"Hypertension","drugRate":"36.4%","placeboRate":"","totalAtRisk":494,"totalAffected":180,"trialsReporting":6},{"effect":"Diarrhoea","drugRate":"44.7%","placeboRate":"","totalAtRisk":356,"totalAffected":159,"trialsReporting":2},{"effect":"Proteinuria","drugRate":"34.3%","placeboRate":"","totalAtRisk":440,"totalAffected":151,"trialsReporting":4},{"effect":"Platelet count decreased","drugRate":"25.0%","placeboRate":"","totalAtRisk":529,"totalAffected":132,"trialsReporting":8},{"effect":"Vomiting","drugRate":"25.3%","placeboRate":"","totalAtRisk":502,"totalAffected":127,"trialsReporting":7},{"effect":"Neutrophil count decreased","drugRate":"22.3%","placeboRate":"","totalAtRisk":529,"totalAffected":118,"trialsReporting":8},{"effect":"Hypothyroidism","drugRate":"32.7%","placeboRate":"","totalAtRisk":321,"totalAffected":105,"trialsReporting":2},{"effect":"Decreased appetite","drugRate":"29.2%","placeboRate":"","totalAtRisk":356,"totalAffected":104,"trialsReporting":2},{"effect":"Abdominal pain","drugRate":"21.1%","placeboRate":"","totalAtRisk":489,"totalAffected":103,"trialsReporting":6},{"effect":"Constipation","drugRate":"18.1%","placeboRate":"","totalAtRisk":502,"totalAffected":91,"trialsReporting":7},{"effect":"Aspartate aminotransferase increased","drugRate":"18.2%","placeboRate":"","totalAtRisk":494,"totalAffected":90,"trialsReporting":6},{"effect":"Anemia","drugRate":"52.5%","placeboRate":"","totalAtRisk":160,"totalAffected":84,"trialsReporting":5},{"effect":"Diarrhea","drugRate":"45.7%","placeboRate":"","totalAtRisk":173,"totalAffected":79,"trialsReporting":6},{"effect":"Weight decreased","drugRate":"20.8%","placeboRate":"","totalAtRisk":356,"totalAffected":74,"trialsReporting":2},{"effect":"Anaemia","drugRate":"19.9%","placeboRate":"","totalAtRisk":356,"totalAffected":71,"trialsReporting":2},{"effect":"Alanine aminotransferase increased","drugRate":"14.2%","placeboRate":"","totalAtRisk":494,"totalAffected":70,"trialsReporting":6},{"effect":"Asthenia","drugRate":"17.7%","placeboRate":"","totalAtRisk":356,"totalAffected":63,"trialsReporting":2},{"effect":"Arthralgia","drugRate":"13.9%","placeboRate":"","totalAtRisk":452,"totalAffected":63,"trialsReporting":5},{"effect":"Blood bilirubin increased","drugRate":"13.7%","placeboRate":"","totalAtRisk":452,"totalAffected":62,"trialsReporting":5},{"effect":"Palmar-plantar erythrodysaesthesia syndrome","drugRate":"17.4%","placeboRate":"","totalAtRisk":356,"totalAffected":62,"trialsReporting":2},{"effect":"Dysphonia","drugRate":"17.1%","placeboRate":"","totalAtRisk":356,"totalAffected":61,"trialsReporting":2},{"effect":"White blood cell decreased","drugRate":"32.4%","placeboRate":"","totalAtRisk":173,"totalAffected":56,"trialsReporting":6},{"effect":"Headache","drugRate":"12.3%","placeboRate":"","totalAtRisk":447,"totalAffected":55,"trialsReporting":5},{"effect":"Back pain","drugRate":"11.0%","placeboRate":"","totalAtRisk":489,"totalAffected":54,"trialsReporting":6},{"effect":"Neutropenia","drugRate":"13.8%","placeboRate":"","totalAtRisk":369,"totalAffected":51,"trialsReporting":3},{"effect":"Anorexia","drugRate":"30.0%","placeboRate":"","totalAtRisk":160,"totalAffected":48,"trialsReporting":5},{"effect":"Pyrexia","drugRate":"12.6%","placeboRate":"","totalAtRisk":356,"totalAffected":45,"trialsReporting":2},{"effect":"Stomatitis","drugRate":"12.1%","placeboRate":"","totalAtRisk":356,"totalAffected":43,"trialsReporting":2},{"effect":"Rash","drugRate":"11.2%","placeboRate":"","totalAtRisk":356,"totalAffected":40,"trialsReporting":2},{"effect":"Urinary tract infection","drugRate":"8.6%","placeboRate":"","totalAtRisk":440,"totalAffected":38,"trialsReporting":4},{"effect":"Hypoalbuminaemia","drugRate":"10.7%","placeboRate":"","totalAtRisk":356,"totalAffected":38,"trialsReporting":2},{"effect":"Blood thyroid stimulating hormone increased","drugRate":"13.3%","placeboRate":"","totalAtRisk":279,"totalAffected":37,"trialsReporting":1},{"effect":"Lymphocyte count decreased","drugRate":"14.8%","placeboRate":"","totalAtRisk":250,"totalAffected":37,"trialsReporting":7},{"effect":"Alopecia","drugRate":"16.2%","placeboRate":"","totalAtRisk":228,"totalAffected":37,"trialsReporting":6},{"effect":"Cough","drugRate":"8.5%","placeboRate":"","totalAtRisk":411,"totalAffected":35,"trialsReporting":4},{"effect":"Myalgia","drugRate":"8.3%","placeboRate":"","totalAtRisk":411,"totalAffected":34,"trialsReporting":4},{"effect":"Insomnia","drugRate":"6.6%","placeboRate":"","totalAtRisk":502,"totalAffected":33,"trialsReporting":7},{"effect":"Epistaxis","drugRate":"6.7%","placeboRate":"","totalAtRisk":462,"totalAffected":31,"trialsReporting":5},{"effect":"Thrombocytopenia","drugRate":"8.1%","placeboRate":"","totalAtRisk":369,"totalAffected":30,"trialsReporting":3},{"effect":"Blood alkaline phosphatase increased","drugRate":"8.4%","placeboRate":"","totalAtRisk":356,"totalAffected":30,"trialsReporting":2},{"effect":"White blood cell count decreased","drugRate":"8.4%","placeboRate":"","totalAtRisk":356,"totalAffected":30,"trialsReporting":2},{"effect":"Dizziness","drugRate":"6.6%","placeboRate":"","totalAtRisk":453,"totalAffected":30,"trialsReporting":5},{"effect":"Abdominal pain upper","drugRate":"8.1%","placeboRate":"","totalAtRisk":356,"totalAffected":29,"trialsReporting":2},{"effect":"Oedema peripheral","drugRate":"8.1%","placeboRate":"","totalAtRisk":356,"totalAffected":29,"trialsReporting":2},{"effect":"Dry mouth","drugRate":"6.4%","placeboRate":"","totalAtRisk":440,"totalAffected":28,"trialsReporting":4},{"effect":"COVID-19","drugRate":"9.7%","placeboRate":"","totalAtRisk":279,"totalAffected":27,"trialsReporting":1},{"effect":"Rash acneiform","drugRate":"29.8%","placeboRate":"","totalAtRisk":84,"totalAffected":25,"trialsReporting":2},{"effect":"Blood creatinine increased","drugRate":"6.7%","placeboRate":"","totalAtRisk":356,"totalAffected":24,"trialsReporting":2}]},"_chembl":null,"allNames":"trifluridine and tipiracil hydrochloride","_dailymed":null,"mechanism":{"target":"TYMS","drugClass":"Antimetabolite","explanation":"This drug combination works by blocking an enzyme called thymidylate synthase, which is crucial for DNA replication. By inhibiting this enzyme, the drug prevents cancer cells from dividing and growing.","oneSentence":"Trifluridine and tipiracil hydrochloride inhibit thymidylate synthase and DNA synthesis, leading to cell death in cancer cells."},"_scrapedAt":"2026-03-28T04:11:36.804Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:56:39.795822+00:00","fieldsConflicting":0,"overallConfidence":0.95},"trialDetails":[{"nctId":"NCT07492173","phase":"NA","title":"Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans","status":"COMPLETED","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2022-11-21","conditions":"Solid Tumor Cancer","enrollment":76},{"nctId":"NCT04511039","phase":"PHASE1","title":"Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2021-06-08","conditions":"Advanced Malignant Solid Neoplasm, Clinical Stage III Gastroesophageal Junction Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma","enrollment":45},{"nctId":"NCT04109924","phase":"PHASE2","title":"TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-27","conditions":"Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma","enrollment":42},{"nctId":"NCT04776148","phase":"PHASE3","title":"Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-03-29","conditions":"Colorectal Neoplasms","enrollment":563},{"nctId":"NCT03844620","phase":"PHASE2","title":"Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-01-29","conditions":"Refractory Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8","enrollment":100},{"nctId":"NCT03869892","phase":"PHASE3","title":"Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut de Recherches Internationales Servier","startDate":"2019-03-21","conditions":"Metastatic Colorectal Cancer","enrollment":856},{"nctId":"NCT04417699","phase":"PHASE2","title":"SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer","status":"COMPLETED","sponsor":"Providence Health & Services","startDate":"2022-07-05","conditions":"Rectal Cancer","enrollment":13},{"nctId":"NCT05438459","phase":"PHASE1, PHASE2","title":"GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites","status":"RECRUITING","sponsor":"Kyushu University","startDate":"2022-06-08","conditions":"Gastric Cancer, Pancreatic Cancer","enrollment":130},{"nctId":"NCT04104139","phase":"PHASE1","title":"TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2019-12-11","conditions":"Rectal Adenocarcinoma, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8","enrollment":19},{"nctId":"NCT07212933","phase":"PHASE2","title":"The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-07-01","conditions":"Gastric (Stomach) Cancer, Biological Therapy, Immunotherapy","enrollment":90},{"nctId":"NCT06764680","phase":"PHASE2","title":"Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-12-31","conditions":"Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy","enrollment":57},{"nctId":"NCT04097028","phase":"PHASE2","title":"Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"2019-12-20","conditions":"Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8","enrollment":22},{"nctId":"NCT06872606","phase":"PHASE2","title":"Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-04-01","conditions":"Rectal Adenocarcinoma","enrollment":33},{"nctId":"NCT03368963","phase":"PHASE1, PHASE2","title":"TAS102 in Combination With NAL-IRI in Advanced GI Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2018-01-30","conditions":"Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma","enrollment":64},{"nctId":"NCT04294264","phase":"PHASE2","title":"TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2019-02-12","conditions":"Metastatic Colorectal Carcinoma, Recurrent Colon Carcinoma, Refractory Colorectal Carcinoma","enrollment":50},{"nctId":"NCT05356897","phase":"PHASE2","title":"Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study","status":"WITHDRAWN","sponsor":"Academic and Community Cancer Research United","startDate":"2023-10-31","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma","enrollment":""},{"nctId":"NCT03981614","phase":"PHASE2","title":"Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer","status":"COMPLETED","sponsor":"Academic and Community Cancer Research United","startDate":"2019-10-29","conditions":"Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8","enrollment":102},{"nctId":"NCT02743221","phase":"PHASE2","title":"A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2016-04-29","conditions":"Metastatic Colorectal Cancer","enrollment":154},{"nctId":"NCT05130060","phase":"PHASE1","title":"A Vaccine (PolyPEPI1018 Vaccine) and TAS-102 for the Treatment of Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2022-01-10","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Colorectal Carcinoma","enrollment":15},{"nctId":"NCT02848443","phase":"PHASE1","title":"Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2016-05","conditions":"Metastatic Colorectal Cancer","enrollment":78},{"nctId":"NCT03306394","phase":"PHASE3","title":"A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Cancer That Has Spread (Metastatic).","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2016-10-18","conditions":"Metastatic Colorectal Cancer","enrollment":907},{"nctId":"NCT03274882","phase":"PHASE2","title":"Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2017-03-03","conditions":"Metastatic Colorectal Cancer","enrollment":26},{"nctId":"NCT03992456","phase":"PHASE2","title":"Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2020-04-24","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma","enrollment":12},{"nctId":"NCT03317119","phase":"PHASE1","title":"Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2018-04-11","conditions":"Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Carcinoma","enrollment":26},{"nctId":"NCT04660760","phase":"PHASE2","title":"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2021-06-16","conditions":"Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8","enrollment":116},{"nctId":"NCT06293014","phase":"PHASE2","title":"TAS-102 Combined With Bevacizumab for Second-line Maintenance Treatment of Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2024-02-23","conditions":"Colorectal Cancer","enrollment":224},{"nctId":"NCT05007132","phase":"PHASE2","title":"Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2021-12-17","conditions":"Metastatic Colorectal Cancer","enrollment":153},{"nctId":"NCT04072445","phase":"PHASE2","title":"Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2019-10-18","conditions":"Advanced Bile Duct Carcinoma, Advanced Gallbladder Carcinoma, Refractory Bile Duct Carcinoma","enrollment":28},{"nctId":"NCT03278106","phase":"PHASE2","title":"TAS-102 in Treating Advanced Biliary Tract Cancers","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-10-20","conditions":"Cholangiocarcinoma, Stage III Gallbladder Cancer AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7","enrollment":28},{"nctId":"NCT03297710","phase":"PHASE1","title":"TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-12-11","conditions":"Rectal Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IV Rectal Cancer AJCC v7","enrollment":7},{"nctId":"NCT04076761","phase":"PHASE2","title":"Study of TRIFLURIDINE/TIPIRACIL in Previously Treated Cholangiocarcinoma","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2019-12-11","conditions":"Cholangiocarcinoma, Bile Duct Cancer","enrollment":8},{"nctId":"NCT04965870","phase":"","title":"A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece","status":"COMPLETED","sponsor":"Hellenic Study Group of Psychoneuroimmunology in Cancer","startDate":"2021-06-30","conditions":"Metastatic Colorectal Cancer","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Trifluridine and Tipiracil Hydrochloride","genericName":"trifluridine-and-tipiracil-hydrochloride","companyName":"Pfizer Inc.","companyId":"pfizer","modality":"","firstApprovalDate":"","aiSummary":"","enrichmentLevel":5,"visitCount":4,"trialStats":{"total":23,"withResults":9},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T08:56:39.795822+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}